AIMS: The European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis - Intravascular Ultrasound (ATHEROREMO-IVUS) study aims to investigate the relations of genetic profile and novel circulating biomarkers with coronary plaque phenotype and vulnerability as determined by intravascular ultrasound (IVUS). METHODS AND RESULTS: ATHEROREMO-IVUS is a prospective, observational cohort study of 846 patients with stable angina pectoris or acute coronary syndrome (ACS) who are referred for coronary angiography. Prior to the catheterisation procedure, blood samples are drawn for biomarker measurements and genetic analyses. During the catheterisation procedure, IVUS is performed in a non-culprit coronary artery. The primary endpoint is the presence of vulnerable plaque as determined by IVUS virtual histology. Secondary endpoints include the incidence of major adverse cardiac events during long-term follow-up. CONCLUSIONS: Results from ATHEROREMO-IVUS are expected to improve our knowledge of the role of genetic profile and circulating biomarkers in relation to the development of atherosclerosis and vulnerable plaques. Assessment and early validation of the prognostic value of novel biomarkers and intracoronary imaging techniques will be performed. (ClinicalTrials.gov number: NCT01789411).
AIMS: The European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis - Intravascular Ultrasound (ATHEROREMO-IVUS) study aims to investigate the relations of genetic profile and novel circulating biomarkers with coronary plaque phenotype and vulnerability as determined by intravascular ultrasound (IVUS). METHODS AND RESULTS: ATHEROREMO-IVUS is a prospective, observational cohort study of 846 patients with stable angina pectoris or acute coronary syndrome (ACS) who are referred for coronary angiography. Prior to the catheterisation procedure, blood samples are drawn for biomarker measurements and genetic analyses. During the catheterisation procedure, IVUS is performed in a non-culprit coronary artery. The primary endpoint is the presence of vulnerable plaque as determined by IVUS virtual histology. Secondary endpoints include the incidence of major adverse cardiac events during long-term follow-up. CONCLUSIONS: Results from ATHEROREMO-IVUS are expected to improve our knowledge of the role of genetic profile and circulating biomarkers in relation to the development of atherosclerosis and vulnerable plaques. Assessment and early validation of the prognostic value of novel biomarkers and intracoronary imaging techniques will be performed. (ClinicalTrials.gov number: NCT01789411).
Authors: Sharda Anroedh; Mika Hilvo; K Martijn Akkerhuis; Dimple Kauhanen; Kaisa Koistinen; Rohit Oemrawsingh; Patrick Serruys; Robert-Jan van Geuns; Eric Boersma; Reijo Laaksonen; Isabella Kardys Journal: J Lipid Res Date: 2018-06-01 Impact factor: 5.922
Authors: Sharda S Anroedh; K Martijn Akkerhuis; Rohit M Oemrawsingh; Hector M Garcia-Garcia; Milos Brankovic; Evelyn Regar; Robert-Jan van Geuns; Patrick W Serruys; Joost Daemen; Nicolas M van Mieghem; Eric Boersma; Isabella Kardys Journal: Curr Atheroscler Rep Date: 2018-09-14 Impact factor: 5.113
Authors: Nermina Buljubasic; K Martijn Akkerhuis; Sanneke P M de Boer; Jin M Cheng; Hector M Garcia-Garcia; Mattie J Lenzen; Rohit M Oemrawsingh; Linda C Battes; Melissa Rijndertse; Evelyn Regar; Patrick W Serruys; Robert-Jan van Geuns; Eric Boersma; Isabella Kardys Journal: PLoS One Date: 2015-10-22 Impact factor: 3.240
Authors: Maxime M Vroegindewey; Anne-Sophie Schuurman; Rohit M Oemrawsingh; Robert-Jan van Geuns; Isabella Kardys; Jurgen Ligthart; Joost Daemen; Eric Boersma; Patrick W Serruys; K Martijn Akkerhuis Journal: PLoS One Date: 2018-07-02 Impact factor: 3.240
Authors: Bárbara Campos Abreu Marino; Nermina Buljubasic; Martijn Akkerhuis; Jin M Cheng; Hector M Garcia-Garcia; Evelyn Regar; Robert-Jan van Geuns; Patrick W Serruys; Eric Boersma; Isabella Kardys Journal: Arq Bras Cardiol Date: 2018-09 Impact factor: 2.000